Evidence map›Paper›PMID 37580757›Full record

ArticleJournal of biomedical science2023

The RNA-binding protein KSRP aggravates malignant progression of clear cell renal cell carcinoma through transcriptional inhibition and post-transcriptional destabilization of the NEDD4L ubiquitin ligase.

Yi-Chieh Yang, Yung-Wei Lin, Wei-Jiunn Lee, Feng-Ru Lai, Kuo-Hao Ho, Chih-Ying Chu, Kuo-Tai Hua, Ji-Qing Chen, Min-Che Tung, Michael Hsiao and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Journal of biomedical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. RNA-Binding Proteins: Modulators of Canonical Wnt Signaling Pathway.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. The roles of the ubiquitin-proteasome system in renal disease.International journal of medical sciences · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Yi-Chieh Yang *Department of Medical Research, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan.
Yung-Wei Lin *International Master/PhD Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Wei-Jiunn LeeGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, 250 Wu Hsing Street, Taipei, 11031, Taiwan.
Feng-Ru LaiGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, 250 Wu Hsing Street, Taipei, 11031, Taiwan.
Kuo-Hao HoGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, 250 Wu Hsing Street, Taipei, 11031, Taiwan.
Chih-Ying ChuGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, 250 Wu Hsing Street, Taipei, 11031, Taiwan.
Kuo-Tai HuaGraduate Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Ji-Qing ChenGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, 250 Wu Hsing Street, Taipei, 11031, Taiwan.
Min-Che TungDepartment of Surgery, Tungs' Taichung Metro Harbor Hospital, Taichung, Taiwan.
Michael HsiaoGenomics Research Center, Academia Sinica, Taipei, Taiwan.
Yu-Ching WenDepartment of Urology, Wan Fang Hospital, Taipei Medical University, 111, Section 3, Hsing Long Road, Taipei, 11696, Taiwan. 95207@w.tmu.edu.tw.
Ming-Hsien ChienGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, 250 Wu Hsing Street, Taipei, 11031, Taiwan. mhchien1976@gmail.com.ORCID http://orcid.org/0000-0002-0084-7231
Taipei Medical University · TWTaipei Medical University Hospital · TWTungs' Taichung MetroHarbor Hospital · TWWan Fang Hospital · TWDartmouth College · USGenomics Research Center, Academia Sinica · TWNational Taiwan University · TW

Funding

Ministry of Science and Technology, Taiwan 109-2320-B-038-052-MY3Taipei Medical University 111-TMU-WFH-01Wan Fang Hospital 111-wf-swf-01
6 · The paper itself

Abstract

backgroundKH-type splicing regulatory protein (KHSRP, also called KSRP), a versatile RNA-binding protein, plays a critical role in various physiological and pathological conditions through modulating gene expressions at multiple levels. However, the role of KSRP in clear cell renal cell carcinoma (ccRCC) remains poorly understood.

methodsKSRP expression was detected by a ccRCC tissue microarray and evaluated by an in silico analysis. Cell loss-of-function and gain-of-function, colony-formation, anoikis, and transwell assays, and an orthotopic bioluminescent xenograft model were conducted to determine the functional role of KRSP in ccRCC progression. Micro (mi)RNA and complementary (c)DNA microarrays were used to identify downstream targets of KSRP. Western blotting, quantitative real-time polymerase chain reaction, and promoter- and 3-untranslated region (3'UTR)-luciferase reporter assays were employed to validate the underlying mechanisms of KSRP which aggravate progression of ccRCC.

resultsOur results showed that dysregulated high levels of KSRP were correlated with advanced clinical stages, larger tumor sizes, recurrence, and poor prognoses of ccRCC. Neural precursor cell-expressed developmentally downregulated 4 like (NEDD4L) was identified as a novel target of KSRP, which can reverse the protumorigenic and prometastatic characteristics as well as epithelial-mesenchymal transition (EMT) promotion by KSRP in vitro and in vivo. Molecular studies revealed that KSRP can decrease NEDD4L messenger (m)RNA stability via inducing mir-629-5p upregulation and directly targeting the AU-rich elements (AREs) of the 3'UTR. Moreover, KSRP was shown to transcriptionally suppress NEDD4L via inducing the transcriptional repressor, Wilm's tumor 1 (WT1). In the clinic, ccRCC samples revealed a positive correlation between KSRP and mesenchymal-related genes, and patients expressing high KSRP and low NEDD4L had the worst prognoses.

conclusionThe current findings unveil novel mechanisms of KSRP which promote malignant progression of ccRCC through transcriptional inhibition and post-transcriptional destabilization of NEDD4L transcripts. Targeting KSRP and its pathways may be a novel pharmaceutical intervention for ccRCC.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsMicroRNAsRNA-Binding Proteins3' Untranslated RegionsCell Line, TumorCell ProliferationHumansNedd4 Ubiquitin Protein LigasesTrans-ActivatorsUbiquitin3' Untranslated RegionsKHSRP protein, humanMicroRNAsMIRN629 microRNA, humanNedd4L protein, humanNedd4 Ubiquitin Protein LigasesRNA-Binding ProteinsTrans-ActivatorsUbiquitinccRCCEMTKSRPNEDD4LProgression

Identifiers

PMID37580757
PMCPMC10424398
OpenAlexW4385810337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.